Date published: 2025-9-11

1-800-457-3801

SCBT Portrait Logo
Seach Input

LOC645781 Inhibitors

Functional inhibition of the protein LOC645781 can be mediated through the modulation of the TGF-β signaling pathway, which is a critical cellular communication route that influences numerous biological processes. Compounds that inhibit the TGF-β pathway often do so by targeting the kinase activity of receptors such as ALK4, ALK5, and ALK7, which are essential for the propagation of TGF-β signals. For example, compounds like SB431542, A-83-01, and RepSox directly inhibit the kinase activity of these receptors, which would diminish the phosphorylation of Smad proteins. The phosphorylation of Smad2 and Smad3 is a prerequisite for their nuclear translocation and subsequent transcriptional regulation of target genes. Thus, if LOC645781's function is contingent upon Smad-mediated transcription, these inhibitors would effectively reduce its activity by preventing Smad activation.

Moreover, compounds such as LY364947 and LY2109761 block the ATP-binding sites of TGF-β type I receptors, which impairs the phosphorylation cascade of Smad proteins. By inhibiting this step, these compounds prevent the activation of the downstream signaling components, including transcription factors that regulate gene expression. If LOC645781 is a gene product whose expression is regulated by such transcription factors, then its functional activity would be diminished as a result of the use of these inhibitors.

SEE ALSO...

Items 11 to 11 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Tranilast

53902-12-8sc-200389
sc-200389A
sc-200389B
sc-200389C
10 mg
50 mg
1 g
5 g
$30.00
$101.00
$277.00
$959.00
2
(1)

Tranilast is an anti-allergic drug that has been shown to inhibit TGF-β release and signaling, possibly affecting Smad phosphorylation. If LOC645781 is regulated by TGF-β-mediated responses, its activity could be indirectly inhibited by Tranilast.